Sab Biotherapeutics Stock Total Debt
| SABSW Stock | USD 0.03 0 14.34% |
SAB Biotherapeutics fundamentals help investors to digest information that contributes to SAB Biotherapeutics' financial success or failures. It also enables traders to predict the movement of SAB Stock. The fundamental analysis module provides a way to measure SAB Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SAB Biotherapeutics stock.
Total Debt To Capitalization is likely to drop to 0.10 in 2025. SAB | Total Debt |
SAB Biotherapeutics Company Total Debt Analysis
SAB Biotherapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current SAB Biotherapeutics Total Debt | 5.91 M |
Most of SAB Biotherapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SAB Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
SAB Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for SAB Biotherapeutics is extremely important. It helps to project a fair market value of SAB Stock properly, considering its historical fundamentals such as Total Debt. Since SAB Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SAB Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SAB Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
SAB Total Debt Historical Pattern
Today, most investors in SAB Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various SAB Biotherapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of SAB Biotherapeutics total debt as a starting point in their analysis.
SAB Biotherapeutics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
SAB Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, SAB Biotherapeutics has a Total Debt of 5.91 M. This is 99.79% lower than that of the Biotechnology sector and 98.18% lower than that of the Health Care industry. The total debt for all United States stocks is 99.89% higher than that of the company.
SAB Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.SAB Biotherapeutics is currently under evaluation in total debt category among its peers.
SAB Fundamentals
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Number Of Shares Shorted | 1.18 K | ||||
| Price To Earning | 0.21 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (25.38 M) | ||||
| EBITDA | (38.13 M) | ||||
| Net Income | (42.19 M) | ||||
| Total Debt | 5.91 M | ||||
| Book Value Per Share | 4.00 X | ||||
| Cash Flow From Operations | (25.12 M) | ||||
| Earnings Per Share | 0.29 X | ||||
| Number Of Employees | 57 | ||||
| Beta | 0.45 | ||||
| Total Asset | 83.94 M | ||||
| Retained Earnings | (90.06 M) | ||||
| Working Capital | 48.09 M | ||||
| Net Asset | 83.94 M |
About SAB Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.